Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

DiaMedica Therapeutics (DMAC) Operating Leases (2019 - 2026)

DiaMedica Therapeutics filings provide 8 years of Operating Leases readings, the most recent being $200000.0 for Q1 2026.

  • Quarterly Operating Leases fell 31.97% to $200000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $200000.0 through Mar 2026, down 31.97% year-over-year, with the annual reading at $124000.0 for FY2025, 44.89% down from the prior year.
  • Operating Leases hit $200000.0 in Q1 2026 for DiaMedica Therapeutics, up from $124000.0 in the prior quarter.
  • Across five years, Operating Leases topped out at $459000.0 in Q3 2022 and bottomed at $28000.0 in Q1 2022.
  • Average Operating Leases over 5 years is $290235.3, with a median of $294000.0 recorded in 2024.
  • Peak annual rise in Operating Leases hit 13100.0% in 2022, while the deepest fall reached 69.23% in 2022.
  • DiaMedica Therapeutics' Operating Leases stood at $396000.0 in 2022, then dropped by 20.2% to $316000.0 in 2023, then dropped by 28.8% to $225000.0 in 2024, then tumbled by 44.89% to $124000.0 in 2025, then skyrocketed by 61.29% to $200000.0 in 2026.
  • Per Business Quant, the three most recent readings for DMAC's Operating Leases are $200000.0 (Q1 2026), $124000.0 (Q4 2025), and $150000.0 (Q3 2025).